Strategies To Prevent Cardiac Allograft Vasculopathy Related Events in Heart Transplant Recipients
Status:
Withdrawn
Trial end date:
2015-01-01
Target enrollment:
Participant gender:
Summary
1. Early initiation of sirolimus will prevent or delay the development of intimal
thickening and subsequent graft failure.
2. Treatment guided by the development of cardiac allograft vasculopathy (CAV) on
intravascular ultrasound (IVUS) will be more effective in delaying progression of CAV
compared to treatment guided by angiography.
3. Prevention of the development and progression of intimal thickness on IVUS will prevent
the development of heart failure, graft dysfunction, and cardiovascular death related to
CAV.
4. Small artery elasticity predicts progression of cardiac allograft vasculopathy and is
modified by sirolimus
5. Patients who have no progression of CAV will have favorable improvement in biomarkers
and endothelial cells compared to patients who have progression of CAV
Phase:
N/A
Details
Lead Sponsor:
University of Minnesota University of Minnesota - Clinical and Translational Science Institute